GILEAD SCIENCES (GIS BE) stock market data APIs
€95.3916
0(0%)
as of July 8, 2025
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.BE.
Prev. Close
95.3916
Open
95.3916
High
95.3916
Low
95.3916
52 wk Range
61.4481-108.5967
Market Cap
78 028 M
Dividends (Yield)
0.0266
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time fr...
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at t...
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc.�...
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
Company Logo The global chronic hepatitis B market is experiencing growth due to breakthroughs in diagnosis and treatment, including gene-editing and immune modulation therapies. With therapies advan...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
